Clinical Trials | November 16, 2025
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Fenebrutinib targets cells in the immune system known as B cells and microglia
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Subscribe To Our Newsletter & Stay Updated
